The Reason 2 O O
[tuberculosis Reason 2 O O
vaccine Reason 2 O O
BCG Reason 2 O O
](https://www.nejm.org/doi/10.1056/NEJMoa2212616)was Reason 2 O O
not Reason 2 O O
protective Reason 2 O O
against Reason 2 O O
COVID-19 Reason 2 O O
infections Reason 2 O O
in Reason 2 O O
healthcare Reason 2 O O
workers, Reason 2 O O
according Reason 2 O O
to Reason 2 O O
the Reason 2 O O
results Reason 2 O O
of Reason 2 O O
an Reason 2 O O
international Reason 2 O O
trial Reason 2 O O
in Reason 2 O O
the Reason 2 O O
New Reason 2 ScientificAuthority O
England Reason 2 ScientificAuthority O
Journal Reason 2 ScientificAuthority O
of Reason 2 ScientificAuthority O
Medicine. Reason 2 ScientificAuthority O
The Reason 3 O O
study Reason 3 O O
was Reason 3 O O
based Reason 3 O O
on Reason 3 O O
results Reason 3 O O
from Reason 3 O O
the Reason 3 O O
second Reason 3 O O
stage Reason 3 O O
of Reason 3 O O
the Reason 3 O O
BCG Reason 3 O O
Vaccination Reason 3 O O
to Reason 3 O O
Reduce Reason 3 O O
the Reason 3 O O
Impact Reason 3 O O
of Reason 3 O O
COVID-19 Reason 3 O O
in Reason 3 O O
Healthcare Reason 3 O O
Workers Reason 3 O O
(BRACE) Reason 3 O O
trial, Reason 3 O O
which Reason 3 O O
involved Reason 3 O O
3,988 Reason 3 O O
of Reason 3 O O
almost Reason 3 O O
7,000 Reason 3 O O
healthcare Reason 3 O O
workers Reason 3 O O
who Reason 3 O O
signed Reason 3 O O
up Reason 3 O O
to Reason 3 O O
participate Reason 3 O O
across Reason 3 O O
36 Reason 3 O O
sites Reason 3 O O
in Reason 3 O O
Australia, Reason 3 O O
the Reason 3 O O
Netherlands, Reason 3 O O
the Reason 3 O O
United Reason 3 O O
Kingdom, Reason 3 O O
Spain, Reason 3 O O
and Reason 3 O O
Brazil. Reason 3 O O
The Reason 3 O O
goal Reason 3 O O
of Reason 3 O O
the Reason 3 O O
BRACE Reason 3 O O
trial Reason 3 O O
was Reason 3 O O
to Reason 3 O O
see Reason 3 O O
if Reason 3 O O
the Reason 3 O O
BCG Reason 3 O O
vaccine Reason 3 O O
could Reason 3 O O
offer Reason 3 O O
protection Reason 3 O O
to Reason 3 O O
healthcare Reason 3 O O
workers Reason 3 O O
during Reason 3 O O
the Reason 3 O O
first Reason 3 O O
months Reason 3 O O
of Reason 3 O O
the Reason 3 O O
COVID-19 Reason 3 O O
pandemic, Reason 3 O O
because Reason 3 O O
the Reason 3 O O
vaccine Reason 3 O O
has Reason 3 O O
a Reason 3 O O
history Reason 3 O O
of Reason 3 O O
being Reason 3 O O
broadly Reason 3 O O
protective Reason 3 O O
against Reason 3 O O
respiratory Reason 3 O O
infections Reason 3 O O
in Reason 3 O O
infants Reason 3 O O
and Reason 3 O O
adults. Reason 3 O O
The Reason 3 O O
hope Reason 3 O O
was Reason 3 O O
BCG Reason 3 O O
could Reason 3 O O
act Reason 3 O O
as Reason 3 O O
a Reason 3 O O
stop-gap Reason 3 O O
vaccine Reason 3 O O
until Reason 3 O O
COVID-specific Reason 3 O O
vaccines Reason 3 O O
were Reason 3 O O
made Reason 3 O O
available. Reason 3 O O
Participants O O O O
in O O O O
the O O O O
second O O O O
stage O O O O
of O O O O
the O O O O
trial O O O O
(recruitment O O O O
from O O O O
May O O O O
2020 O O O O
through O O O O
April O O O O
2021) O O O O
were O O O O
separated O O O O
into O O O O
two O O O O
groups, O O O O
1,703 O O O O
in O O O O
the O O O O
BCG O O O O
group O O O O
and O O O O
1,683 O O O O
in O O O O
the O O O O
placebo O O O O
group. O O O O
Participants O O O O
were O O O O
mostly O O O O
women O O O O
(73.7%), O O O O
with O O O O
an O O O O
average O O O O
age O O O O
of O O O O
42 O O O O
years. O O O O
A O O O O
large O O O O
proportion O O O O
of O O O O
the O O O O
participants O O O O
were O O O O
enrolled O O O O
in O O O O
Brazil O O O O
(64.4%). O O O O
The O O O O
participants O O O O
were O O O O
followed O O O O
for O O O O
12 O O O O
months, O O O O
with O O O O
primary O O O O
outcomes O O O O
assessed O O O O
at O O O O
6 O O O O
months, O O O O
which O O O O
included O O O O
the O O O O
incidence O O O O
of O O O O
symptomatic O O O O
COVID-19 O O O O
and O O O O
the O O O O
incidence O O O O
of O O O O
severe O O O O
COVID-19 O O O O
by O O O O
6 O O O O
months O O O O
after O O O O
randomization. O O O O
BCG Reason 2 O O
participants Reason 2 O O
had Reason 2 O O
more Reason 2 O O
symptomatic Reason 2 O O
COVID-19 Reason 2 O O
The Reason 2 O O
risk Reason 2 O O
of Reason 2 O O
symptomatic Reason 2 O O
COVID-19 Reason 2 O O
was Reason 2 O O
14.7% Reason 2 O O
in Reason 2 O O
the Reason 2 O O
BCG Reason 2 O O
group Reason 2 O O
and Reason 2 O O
12.3% Reason 2 O O
in Reason 2 O O
the Reason 2 O O
placebo Reason 2 O O
group Reason 2 O O
during Reason 2 O O
the Reason 2 O O
first Reason 2 O O
6 Reason 2 O O
months Reason 2 O O
of Reason 2 O O
the Reason 2 O O
trial. Reason 2 O O
There Reason 2 O O
were Reason 2 O O
five Reason 2 O O
hospitalizations Reason 2 O O
due Reason 2 O O
to Reason 2 O O
COVID-19 Reason 2 O O
in Reason 2 O O
each Reason 2 O O
group Reason 2 O O
(including Reason 2 O O
one Reason 2 O O
death Reason 2 O O
in Reason 2 O O
the Reason 2 O O
placebo Reason 2 O O
group). Reason 2 O O
Severe O O O O
COVID-19 O O O O
occurred O O O O
in O O O O
75 O O O O
participants O O O O
in O O O O
the O O O O
BCG O O O O
group O O O O
(7.6%) O O O O
and O O O O
in O O O O
61 O O O O
participants O O O O
in O O O O
the O O O O
placebo O O O O
group O O O O
(6.5%). O O O O
Because Reason 2 O O
such Reason 2 O O
low Reason 2 O O
numbers Reason 2 O O
of Reason 2 O O
study Reason 2 O O
participants Reason 2 O O
and Reason 2 O O
severe Reason 2 O O
COVID-19 Reason 2 O O
cases, Reason 2 O O
researchers Reason 2 O O
could Reason 2 O O
not Reason 2 O O
determine Reason 2 O O
whether Reason 2 O O
the Reason 2 O O
vaccine Reason 2 O O
reduced Reason 2 O O
hospitalizations Reason 2 O O
or Reason 2 O O
deaths. Reason 2 O O
The Reason 2 O O
study Reason 2 O O
authors Reason 2 O O
said Reason 2 O O
the Reason 2 O O
BCG Reason 2 O O
vaccine Reason 2 O O
may Reason 2 O O
have Reason 2 O O
primed Reason 2 O O
the Reason 2 O O
immune Reason 2 O O
system Reason 2 O O
to Reason 2 O O
react Reason 2 O O
more Reason 2 O O
strongly Reason 2 O O
to Reason 2 O O
COVID-19 Reason 2 O O
infection. Reason 2 O O
"In Reason 2 O O
theory, Reason 2 O O
an Reason 2 O O
increased Reason 2 O O
risk Reason 2 O O
of Reason 2 O O
symptomatic Reason 2 O O
Covid-19 Reason 2 O O
could Reason 2 O O
be Reason 2 O O
explained Reason 2 O O
by Reason 2 O O
a Reason 2 O O
BCG-induced Reason 2 O O
stronger Reason 2 O O
immune Reason 2 O O
response. Reason 2 O O
BCG-vaccinated Reason 2 O O
participants Reason 2 O O
in Reason 2 O O
the Reason 2 O O
BRACE Reason 2 O O
trial Reason 2 O O
had Reason 2 O O
more Reason 2 O O
activated Reason 2 O O
and Reason 2 O O
effector Reason 2 O O
T Reason 2 O O
cells Reason 2 O O
in Reason 2 O O
response Reason 2 O O
to Reason 2 O O
in Reason 2 O O
vitro Reason 2 O O
SARS-CoV-2 Reason 2 O O
stimulation Reason 2 O O
than Reason 2 O O
controls," Reason 2 O O
the Reason 2 O O
authors Reason 2 O O
said. Reason 2 O O
"These O O O O
effects O O O O
might O O O O
result O O O O
in O O O O
more O O O O
rapid O O O O
clearance O O O O
of O O O O
SARS-CoV-2, O O O O
leading O O O O
to O O O O
a O O O O
shorter O O O O
illness." O O O O
Study O O O O
author O O O O
Nigel O O O O
Curtis, O O O O
PhD O O O O
said O O O O
in O O O O
a O O O O
[press O O O O
release](https://www.eurekalert.org/news-releases/987041) O O O O
on O O O O
the O O O O
study O O O O
that O O O O
this O O O O
effect O O O O
was O O O O
seen O O O O
to O O O O
some O O O O
degree O O O O
in O O O O
older O O O O
study O O O O
participants. O O O O
There Reason 4 O O
was Reason 4 O O
some Reason 4 O O
evidence Reason 4 O O
of Reason 4 O O
this Reason 4 O O
in Reason 4 O O
trial Reason 4 O O
participants Reason 4 O O
over Reason 4 O O
the Reason 4 O O
age Reason 4 O O
of Reason 4 O O
60, Reason 4 O O
in Reason 4 O O
whom Reason 4 O O
COVID-19 Reason 4 O O
symptoms Reason 4 O O
were Reason 4 O O
shorter Reason 4 O O
in Reason 4 O O
the Reason 4 O O
BCG-vaccinated Reason 4 O O
group. Reason 4 O O
"Symptoms Reason 4 O O
reflect Reason 4 O O
the Reason 4 O O
immune Reason 4 O O
system Reason 4 O O
working Reason 4 O O
hard Reason 4 O O
to Reason 4 O O
fight Reason 4 O O
the Reason 4 O O
virus," Reason 4 O O
Curtis Reason 4 O O
said. Reason 4 O O
"A Reason 4 O O
stronger Reason 4 O O
response Reason 4 O O
induced Reason 4 O O
by Reason 4 O O
BCG Reason 4 O O
could Reason 4 O O
be Reason 4 O O
beneficial Reason 4 O O
in Reason 4 O O
killing Reason 4 O O
the Reason 4 O O
virus Reason 4 O O
more Reason 4 O O
rapidly Reason 4 O O
and Reason 4 O O
protecting Reason 4 O O
against Reason 4 O O
progression Reason 4 O O
to Reason 4 O O
more Reason 4 O O
severe Reason 4 O O
disease. Reason 4 O O
There Reason 4 O O
was Reason 4 O O
some Reason 4 O O
evidence Reason 4 O O
of Reason 4 O O
this Reason 4 O O
in Reason 4 O O
trial Reason 4 O O
participants Reason 4 O O
over Reason 4 O O
the Reason 4 O O
age Reason 4 O O
of Reason 4 O O
60, Reason 4 O O
in Reason 4 O O
whom Reason 4 O O
COVID-19 Reason 4 O O
symptoms Reason 4 O O
were Reason 4 O O
shorter Reason 4 O O
in Reason 4 O O
the Reason 4 O O
BCG-vaccinated Reason 4 O O
group." Reason 4 O O
Of Reason 4 O O
note, Reason 4 O O
75% Reason 4 O O
of Reason 4 O O
all Reason 4 O O
trial Reason 4 O O
participants Reason 4 O O
had Reason 4 O O
previously Reason 4 O O
been Reason 4 O O
given Reason 4 O O
the Reason 4 O O
BCG Reason 4 O O
vaccine. Reason 4 O O
That O O O O
factor O O O O
and O O O O
the O O O O
speedy O O O O
rollout O O O O
of O O O O
COVID-19 O O O O
vaccines O O O O
led O O O O
to O O O O
lower-than-expected O O O O
enrollment O O O O
in O O O O
the O O O O
study. O O O O
Despite O O O O
those O O O O
limitations, O O O O
co-study O O O O
author O O O O
John O O O O
Campbell, O O O O
PhD, O O O O
of O O O O
the O O O O
University O O ScientificAuthority O
of O O ScientificAuthority O
Exeter O O ScientificAuthority O
said O O O O
the O O O O
trial O O O O
represented O O O O
an O O O O
important O O O O
opportunity O O O O
to O O O O
test O O O O
the O O O O
potential O O O O
of O O O O
the O O O O
BCG O O O O
vaccine. O O O O
"The O O O O
findings O O O O
raise O O O O
important O O O O
questions O O O O
about O O O O
how O O O O
BCG O O O O
can O O O O
modify O O O O
the O O O O
course O O O O
of O O O O
different O O O O
viral O O O O
illnesses O O O O
and O O O O
allows O O O O
us O O O O
to O O O O
develop O O O O
a O O O O
fuller O O O O
understanding O O O O
of O O O O
whether O O O O
the O O O O
vaccine O O O O
can O O O O
provide O O O O
protection O O O O
against O O O O
a O O O O
range O O O O
of O O O O
infections O O O O
other O O O O
than O O O O
its O O O O
main O O O O
target, O O O O
tuberculosis," O O O O
he O O O O
said. O O O O
